欧博app下载网址www.aLLbet8.vip)是欧博集团的官方网站。欧博app下载网址开放Allbet注册、Allbe代理、Allbet电脑客户端、Allbet手机版下载等业务。

MIDF Research said while it was positive on the endeavour, the feasibility of the partnership and strategies would not be visible until at least next year.

PETALING JAYA: Pharmaniaga Bhd’s new venture involving the production of halal medicines is expected to bear fruit earliest, by next year.

MIDF Research said while it was positive on the endeavour, the feasibility of the partnership and strategies would not be visible until at least next year.

“We make no changes to our earnings estimates for financial year 2022 (FY22) to FY23, thus maintaining our target price at 91 sen for Pharmaniaga.

“The development of the halal anti-coagulant would not be finalised until approval by the National Pharmaceutical Regulatory Agency by 2024, with the risk of a fallout still an immediate possibility,” it said in a report.

Pharmaniaga said last week that it would commercialise Malaysia’s halal ovine (sheep and goat) anti-coagulant (blood clot thinner) drug in Malaysia by 2024.

The venture is a collaboration with China’s Ronnsi Pharma Co Ltd.

MIDF in its report noted that Covid-19 had added to the need for anti-coagulants in a bid to prevent severe complications from thromboembolism.

“Additionally, ischaemic heart diseases had seen a significant increase by 24% from 2015 to 2020, adding to the need for anti-blood clot agent to ease heart surgery and minimise complication,” it said.

,

环球ug会员开户www.ugbet.us)开放环球UG代理登录网址、会员登录网址、环球UG会员注册、环球UG代理开户申请、环球UG电脑客户端、环球UG手机版下载等业务。

,

It also noted that the anti-coagulant market is expected to reach eight million dosages by 2026. There are big opportunities in halal market, it said.

“Anti-coagulants are used for invasive surgeries, as well as in preventive treatment for cardiovascular and cerebrovascular diseases.

“As most anti-coagulants in the market currently is derived from swine, the demand for halal anti-coagulants is expected to rise.”

It said the venture will position Pharmaniaga as the exclusive registration holder, distributor and manufacturer, with Ronnsi as the patent owner and developer.

It will also contribute to Malaysia’s potential as the first distributor and manufacturer of halal blood anti-coagulants, MIDF said.

In its report, MIDF pointed out that Ronnsi was founded in 2012 and is a pharma company focusing on complex drug research and development, with its main products being Heparin, Enoxaparin and Dalteparin salts.

“Ronnsi is the first developer of non-porcine-based enoxaparin, which has passed all approvals and is currently commercialised globally as an ovine-based anti-coagulant.

“Through this expertise, the group has collaborated with various international companies including from Indonesia, Pakistan, the United States and Italy.”

Still, there are threats to this partnership including pricing pressures and increased competition, MIDF said in its risk analysis.

Allbet声明:该文看法仅代表作者自己,与www.allbetgame.us无关。转载请注明:欧博app下载网址:Big halal medicine market for Pharmaniaga
发布评论

分享到:

三公大吃小(www.eth108.vip):梁振英 八万五不是元凶
1 条回复
  1. 皇冠体育官网(www.hg108.vip)
    皇冠体育官网(www.hg108.vip)
    (2022-11-13 00:03:31) 1#

    摩托车发动机最常见的是单缸,然后从双缸一直到六缸都有,最大的另有美国波斯豪斯的直接使用汽车V8的发动机,固然,五缸的发动机确实很少见,应该只有本田的MOTOGP上的赛车曾经使用过V型五缸的发动机——RC211V,如图。熬夜追完了

发表评论

◎欢迎参与讨论,请在这里发表您的看法、交流您的观点。